Despite dramatic outcomes by the immunotherapy in some cancer patients, treatments with CTLA-4 or PD-1/PD-L1 immune checkpoint blockers were effective only in about 15% to 25% of patients with various cancers [188]. The gene discussed is PDCD1; the disease is cancer.